Solid Biosciences (NASDAQ:SLDB – Free Report) had its price objective boosted by Chardan Capital from $15.00 to $16.00 in a report published on Wednesday morning,Benzinga reports. The brokerage ...

Chardan Capital raised their FY2025 earnings estimates for shares of Solid Biosciences in a research report issued to clients and investors on Wednesday, February 19th. Chardan Capital analyst Y.

In the phase 1/2 INSPIRE DUCHENNE trial, interim data showed an average microdystrophin expression of 110% among participants ...

In a report released today, Gena Wang from Barclays maintained a Hold rating on Beam Therapeutics (BEAM – Research Report), with a price target ...

In a report released today, Silvan Tuerkcan from JMP Securities maintained a Buy rating on Terns Pharmaceuticals (TERN – Research Report), with ...

The life sciences company Solid Biosciences is merging with the privately-held gene therapy company AavantiBio in a deal which is expected to result in a combined sum of $215 million in cash and ...

On The Readout LOUD this week, STAT reporters discuss the FDA's staff cuts, how next-gen drugs may lead to too much weight ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) announced that it has entered into a licensing agreement with Roche (OTC:RHHBY) related to its lead gene therapy candidate, SRP-9001,... Investors in Solid ...

Candel Therapeutics Inc. shares gained momentum as Wall Street analysts highlighted the potential of its lead cancer drug ...

Millie, a modern maternity clinic, secured $12 million in Series A funding led by existing investors RH Capital, TMV, ...

The future of the CDC’s vaccine advisory committee seems uncertain: A scheduled February meeting for the ACIP, which advises ...